VEGF	0	4	B-Gene_or_gene_product
-	4	5	O
targeted	5	13	O
therapy	14	21	O
:	21	22	O
therapeutic	23	34	O
potential	35	44	O
and	45	48	O
recent	49	55	O
advances	56	64	O
.	64	65	O

After	67	72	O
over	73	77	O
30	78	80	O
years	81	86	O
of	87	89	O
theorizing	90	100	O
,	100	101	O
the	102	105	O
use	106	109	O
of	110	112	O
angiogenesis	113	125	O
inhibitors	126	136	O
as	137	139	O
anticancer	140	150	O
therapy	151	158	O
has	159	162	O
finally	163	170	O
moved	171	176	O
from	177	181	O
the	182	185	O
realm	186	191	O
of	192	194	O
research	195	203	O
to	204	206	O
reality	207	214	O
.	214	215	O

Normal	216	222	O
adult	223	228	O
vasculature	229	240	B-Anatomical_system
is	241	243	O
generally	244	253	O
quiescent	254	263	O
in	264	266	O
nature	267	273	O
,	273	274	O
with	275	279	O
endothelial	280	291	B-Cell
cells	292	297	I-Cell
dividing	298	306	O
approximately	307	320	O
every	321	326	O
10	327	329	O
years	330	335	O
.	335	336	O

In	337	339	O
contrast	340	348	O
,	348	349	O
the	350	353	O
growth	354	360	O
of	361	363	O
tumors	364	370	B-Pathological_formation
requires	371	379	O
constant	380	388	O
vascular	389	397	B-Multi-tissue_structure
growth	398	404	O
and	405	408	O
remodeling	409	419	O
in	420	422	O
order	423	428	O
for	429	432	O
solid	433	438	B-Pathological_formation
tumors	439	445	I-Pathological_formation
to	446	448	O
grow	449	453	O
beyond	454	460	O
1	461	462	O
-	462	463	O
2	463	464	O
mm	465	467	O
(	467	468	O
3	468	469	O
)	469	470	O
in	471	473	O
size	474	478	O
.	478	479	O

Vascular	480	488	B-Gene_or_gene_product
endothelial	489	500	I-Gene_or_gene_product
growth	501	507	I-Gene_or_gene_product
factor	508	514	I-Gene_or_gene_product
(	515	516	O
VEGF	516	520	B-Gene_or_gene_product
)	520	521	O
and	522	525	O
its	526	529	O
receptors	530	539	O
are	540	543	O
key	544	547	O
regulators	548	558	O
of	559	561	O
the	562	565	O
process	566	573	O
of	574	576	O
angiogenesis	577	589	O
,	589	590	O
which	591	596	O
makes	597	602	O
them	603	607	O
attractive	608	618	O
therapeutic	619	630	O
targets	631	638	O
.	638	639	O

A	640	641	O
multitude	642	651	O
of	652	654	O
VEGF	655	659	B-Gene_or_gene_product
-	659	660	O
targeted	660	668	O
inhibitory	669	679	O
agents	680	686	O
are	687	690	O
currently	691	700	O
being	701	706	O
investigated	707	719	O
for	720	723	O
the	724	727	O
treatment	728	737	O
of	738	740	O
cancer	741	747	O
.	747	748	O

This	749	753	O
review	754	760	O
article	761	768	O
focuses	769	776	O
on	777	779	O
recent	780	786	O
developments	787	799	O
in	800	802	O
the	803	806	O
use	807	810	O
of	811	813	O
angiogenesis	814	826	O
inhibitors	827	837	O
for	838	841	O
the	842	845	O
treatment	846	855	O
of	856	858	O
breast	859	865	B-Pathological_formation
,	865	866	O
lung	867	871	B-Pathological_formation
,	871	872	O
and	873	876	O
colorectal	877	887	B-Pathological_formation
cancers	888	895	I-Pathological_formation
.	895	896	O

